Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC

[1]  O. Molinier,et al.  Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial , 2020, Clinical Cancer Research.

[2]  Gang Deng,et al.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  Patricia A. Young,et al.  Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. , 2018, Lung cancer.

[4]  A. Jemal,et al.  Higher Lung Cancer Incidence in Young Women Than Young Men in the United States , 2018, The New England journal of medicine.

[5]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[6]  O. Brustugun,et al.  Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer. , 2018, Anticancer research.

[7]  L. Stabile,et al.  The Role of the Estrogen Pathway in the Tumor Microenvironment , 2018, International journal of molecular sciences.

[8]  O. Arrieta,et al.  Influence of estrogen in non-small cell lung cancer and its clinical implications. , 2018, Journal of thoracic disease.

[9]  C. Hsieh,et al.  Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study. , 2017, Cancer epidemiology.

[10]  P. Malmström,et al.  Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen , 2017, Acta oncologica.

[11]  J. Horiguchi,et al.  Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. , 2016, American journal of translational research.

[12]  Y. Prakash,et al.  Sex steroid signaling: implications for lung diseases. , 2015, Pharmacology & therapeutics.

[13]  A. Buqué,et al.  Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer , 2014, PloS one.

[14]  L. Marks,et al.  Lung , 2013, ALERT • Adverse Late Effects of Cancer Treatment.

[15]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Barrios,et al.  Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Goodglick,et al.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. , 2012, Lung cancer management.

[18]  H. Sasano,et al.  Sex steroid receptors in human lung diseases , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  S. Horvath,et al.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. , 2011, Lung cancer.

[20]  Takashi Suzuki,et al.  Suppression of estrogen actions in human lung cancer , 2011, Molecular and Cellular Endocrinology.

[21]  G. Vlastos,et al.  Lung cancer mortality risk among breast cancer patients treated with anti‐estrogens , 2011, Cancer.

[22]  Takashi Suzuki,et al.  Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. , 2010, Cancer research.

[23]  Gustavo H. Esteves,et al.  Early Changes in Gene Expression Induced by Tobacco Smoke: Evidence for the Importance of Estrogen within Lung Tissue , 2010, Cancer Prevention Research.

[24]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[25]  E. White,et al.  Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Aas,et al.  Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  Takashi Suzuki,et al.  Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. , 2010, Human pathology.

[28]  G. Vlastos,et al.  Reduced Lung Cancer Mortality Risk among Breast Cancer Patients Treated with Anti-Estrogens. , 2009 .

[29]  R. Chlebowski.  Menopausal hormone therapy, hormone receptor status, and lung cancer in women. , 2009, Seminars in oncology.

[30]  A. Papavassiliou,et al.  Antiproliferative effect of exemestane in lung cancer cells , 2009, Molecular Cancer.

[31]  J. Manson,et al.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial , 2009, The Lancet.

[32]  J. Siegfried,et al.  Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  M. Fishbein,et al.  Targeting Aromatase and Estrogen Signaling in Human Non‐Small Cell Lung Cancer , 2009, Annals of the New York Academy of Sciences.

[34]  Takashi Suzuki,et al.  Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma , 2008, Clinical Cancer Research.

[35]  S. Badve,et al.  Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. , 2008, Endocrine-related cancer.

[36]  I. Wistuba,et al.  Aromatase expression predicts survival in women with early-stage non small cell lung cancer. , 2007, Cancer research.

[37]  Janakiraman Subramanian,et al.  Lung cancer in never smokers: a review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Fishbein,et al.  Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.

[39]  W. Mcgregor,et al.  Gender difference in the activity but not expression of estrogen receptors α and β in human lung adenocarcinoma cells , 2006 .

[40]  M. Fishbein,et al.  Aromatase inhibitors in human lung cancer therapy. , 2005, Cancer research.

[41]  M. Fishbein,et al.  Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells , 2005, Steroids.

[42]  J. Siegfried,et al.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.

[43]  G. Scagliotti,et al.  Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[45]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[46]  D. Cella,et al.  Quality of life outcomes: measurement and validation. , 1996, Oncology.

[47]  D. Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. , 1995, Lung cancer.

[48]  H. Wakelee,et al.  Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. , 2016, Clinical lung cancer.

[49]  J. Wittliff,et al.  Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. , 2008, Advances in experimental medicine and biology.

[50]  A. Potti,et al.  Hormone replacement therapy is associated with decreased survival in women with lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Mcgregor,et al.  Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. , 2006, Endocrine-related cancer.

[52]  J. Luketich,et al.  Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. , 2002, Cancer research.

[53]  The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. , 1973, JAMA.